A 73-Year-Old Woman With Differentiated Thyroid Cancer

home / case-based-peer-perspectives / a-73-year-old-woman-with-differentiated-thyroid-cancer

Andrew G. Gianoukakis, MD, of Harbor-UCLA Medical Center, describes the rationale for treating a patient with RAI-refractory differentiated thyroid cancer with systemic therapy.

Case Impressions: A 73-Year-Old Woman With DTC

EP. 1: Case Impressions: A 73-Year-Old Woman With DTC

Andrew G. Gianoukakis, MD
September 25th 2020

Watch

Recommendations for Treating Patients With DTC

EP. 2: Recommendations for Treating Patients With DTC

Andrew G. Gianoukakis, MD
September 25th 2020

Watch

Systemic Therapy for RAI-Refractory DTC

EP. 3: Systemic Therapy for RAI-Refractory DTC

Andrew G. Gianoukakis, MD
September 25th 2020

Watch

Lenvatinib Data for RAI-Refractory DTC

EP. 4: Lenvatinib Data for RAI-Refractory DTC

Andrew G. Gianoukakis, MD
September 25th 2020

Watch

Real-World Insight: Lenvatinib for RAI-Refractory DTC

EP. 5: Real-World Insight: Lenvatinib for RAI-Refractory DTC

Andrew G. Gianoukakis, MD
September 25th 2020

Watch

Progress in Treating RAI-Refractory DTC

EP. 6: Progress in Treating RAI-Refractory DTC

Andrew G. Gianoukakis, MD
September 25th 2020

Watch

Higher Dose Cabozantinib Demonstrates Superior Efficacy Over Lower Dose in MTC

EP. 7: Higher Dose Cabozantinib Demonstrates Superior Efficacy Over Lower Dose in MTC

Sara Karlovitch
October 7th 2021

The 140 mg dosage was associated with a higher rate of adverse events and dose reductions.

Read More